Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
The study spanned six months, with assessments at baseline, 3 months, and 6 months
It is a triple GIP/GLP-1/glucagon receptor agonist approved for obesity
AOD-9604 has a plasma half-life of approximately 30 to 60 minutes in humans (subcutaneous)
Regionally, the market is divided into North America, Europe, East Asia, South Asia and Pacific, Latin America, and Middle East and Africa
Rhonda Patrick adds: "By boosting melanocortin pathways, PT-141 addresses a key aspect of sexual health decline in menopause, supporting overall well-being."[19] Ben Greenfield recommends: "PT-141 pairs well for protocols, enhancing response efficiently without the downsides of traditional meds."[17] From X users: "PT-141 transformed my intimacydesire back like in my 20s!" [20] and "Best for reigniting the spark during menopause."[21] These insights underscore PT-141's power, blending science with real-world application for renewed vitality
